Dyne Therapeutics (DYN) Competitors $14.56 +0.61 (+4.37%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$14.73 +0.17 (+1.20%) As of 07:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, TGTX, and CRSPShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Its Competitors Grifols Rhythm Pharmaceuticals Avidity Biosciences Abivax Legend Biotech Cytokinetics Nuvalent Axsome Therapeutics TG Therapeutics CRISPR Therapeutics Dyne Therapeutics (NASDAQ:DYN) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Which has better valuation & earnings, DYN or GRFS? Grifols has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$317.42M-$3.86-3.77Grifols$7.81B0.85$169.80M$1.178.23 Is DYN or GRFS more profitable? Grifols' return on equity of 0.00% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -64.12% -56.75% Grifols N/A N/A N/A Does the media prefer DYN or GRFS? In the previous week, Dyne Therapeutics had 9 more articles in the media than Grifols. MarketBeat recorded 15 mentions for Dyne Therapeutics and 6 mentions for Grifols. Grifols' average media sentiment score of 1.29 beat Dyne Therapeutics' score of 0.78 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, DYN or GRFS? Dyne Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Do analysts prefer DYN or GRFS? Dyne Therapeutics currently has a consensus price target of $34.07, suggesting a potential upside of 133.97%. Grifols has a consensus price target of $10.30, suggesting a potential upside of 6.96%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 2.94Grifols 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Do insiders and institutionals have more ownership in DYN or GRFS? 96.7% of Dyne Therapeutics shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryDyne Therapeutics beats Grifols on 8 of the 15 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.98B$2.62B$6.09B$10.54BDividend YieldN/A56.71%5.69%4.71%P/E Ratio-3.7723.6985.5527.60Price / SalesN/A571.61537.79201.45Price / CashN/A173.2337.9261.55Price / Book2.355.5312.996.76Net Income-$317.42M$32.78M$3.30B$275.88M7 Day Performance16.02%5.82%4.33%2.81%1 Month Performance9.89%13.16%9.48%9.24%1 Year Performance-54.53%1.69%84.61%35.42% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.5266 of 5 stars$14.56+4.4%$34.07+134.0%-56.1%$1.98BN/A-3.77100Analyst ForecastGRFSGrifols3.8651 of 5 stars$9.93+1.1%$10.30+3.7%+9.9%$6.75B$7.81B8.4923,822Positive NewsAnalyst ForecastRYTMRhythm Pharmaceuticals3.5249 of 5 stars$100.64+1.5%$106.64+6.0%+108.4%$6.59B$130.13M0.00140Positive NewsAnalyst ForecastRNAAvidity Biosciences2.2282 of 5 stars$42.63-0.7%$68.32+60.3%+4.2%$6.27B$10.90M0.00190Analyst ForecastInsider TradeABVXAbivax2.9196 of 5 stars$83.33+0.6%$102.14+22.6%+847.5%$6.26BN/A0.0061Analyst ForecastAnalyst RevisionLEGNLegend Biotech2.5959 of 5 stars$32.85-1.6%$74.22+125.9%-33.0%$6.16B$627.24M0.002,609News CoverageAnalyst ForecastCYTKCytokinetics3.7433 of 5 stars$53.89+6.9%$75.71+40.5%+11.9%$6.03B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent2.9495 of 5 stars$84.84+4.2%$119.50+40.9%-17.1%$5.87BN/A0.0040Analyst ForecastAXSMAxsome Therapeutics4.782 of 5 stars$117.62+0.7%$177.86+51.2%+40.0%$5.83B$385.69M0.00380Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionTGTXTG Therapeutics4.4414 of 5 stars$36.83+3.7%$48.00+30.3%+63.7%$5.63B$329M99.54290Trending NewsAnalyst ForecastAnalyst RevisionCRSPCRISPR Therapeutics1.4502 of 5 stars$63.77+3.4%$71.50+12.1%+69.9%$5.61B$37.31M0.00460Analyst Forecast Related Companies and Tools Related Companies Grifols Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Abivax Competitors Legend Biotech Competitors Cytokinetics Competitors Nuvalent Competitors Axsome Therapeutics Competitors TG Therapeutics Competitors CRISPR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
